Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Bristol-Myers Squibb Company    BMY

BRISTOL-MYERS SQUIBB COMPANY (BMY)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
01/10/2019 01/11/2019 01/14/2019 01/15/2019 01/16/2019 Date
47.72(c) 47.99(c) 47.97(c) 49.72(c) 49.13(c) Last
24 947 805 12 470 922 18 296 196 23 116 884 14 961 179 Volume
+1.14% +0.57% -0.04% +3.65% -1.19% Change
More quotes
Financials (USD)
Sales 2018 22 552 M
EBIT 2018 6 173 M
Net income 2018 5 146 M
Finance 2018 1 244 M
Yield 2018 3,34%
Sales 2019 24 196 M
EBIT 2019 6 674 M
Net income 2019 5 918 M
Finance 2019 3 747 M
Yield 2019 3,45%
P/E ratio 2018 15,63
P/E ratio 2019 14,68
EV / Sales2018 3,50x
EV / Sales2019 3,16x
Capitalization 80 190 M
More Financials
Company
Bristol-Myers Squibb Company specializes in the development, manufacturing and marketing of pharmaceutical products. Net sales break down by therapeutic area as follows: - cancers (33.5%); - cardiovascular diseases (23.5%); - viral diseases (19.8%); - immune diseases (11.9%); - psychiatric... 
Sector
Pharmaceuticals
Calendar
01/24 | 06:59amEarnings Release
More about the company
Surperformance© ratings of Bristol-Myers Squibb Compa
Trading Rating : Investor Rating :
More Ratings
Latest news on BRISTOL-MYERS SQUIBB COMPA
01/16Acceleron, Stemline price upsized follow-ons
AQ
01/16BRISTOL-MYERS SQUIBB COMPANY : - European Commission Approves Opdivo Plus Low-Do..
AQ
01/15MSKCC says senior execs may not hold industry board seats
AQ
01/15Ascletis to develop Alphamab's PD-L1 antibody for HBV in China
AQ
01/14BRISTOL MYERS SQUIBB : EC Approves Opdivo Plus Yervoy for Some Patients with Ren..
DJ
01/14BRISTOL MYERS SQUIBB : European Commission Approves Opdivo (nivolumab) Plus Low-..
PU
01/12BRISTOL MYERS SQUIBB : Computational scientists design a new IL-2 cancer drug an..
AQ
01/10ONO PHARMACEUTICAL : Opdivo meets OS endpoint in esophageal cancer trial
AQ
01/08GlaxoSmithKline to look for early-stage assets - CEO
RE
01/08CELGENE INVESTOR ALERT BY THE FORMER : Kahn Swick & Foti, LLC Investigates Adequ..
PR
More news
Analyst Recommendations on BRISTOL-MYERS SQUIBB COMPA
More recommendations
Sector news : Pharmaceuticals - NEC
05:45aSANOFI : Corporate Europe Faces 'Unbearable' Uncertainty Over U.K. Exit
DJ
01/16NOVARTIS : Sandoz Launches EpiPen Generic -- Update
DJ
01/16AMGEN : FDA Panel Recommends Approval of Osteoporosis Drug Evenity Over Safety C..
DJ
01/16NOVARTIS : Sandoz Launches EpiPen Generic
DJ
01/16AMGEN : FDA Panel Recommends Approval of Osteoporosis Drug Evenity Over Safety C..
DJ
More sector news : Pharmaceuticals - NEC
Chart BRISTOL-MYERS SQUIBB COMPANY
Duration : Period :
Bristol-Myers Squibb Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BRISTOL-MYERS SQUIBB COMPA
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 58,5 $
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Giovanni Caforio Chairman & Chief Executive Officer
Johanna Mercier President & Head-US Commercial
Charles A. Bancroft CFO, EVP & Head-Global Business Operations
Paul von Autenried Chief Information Officer & Senior Vice President
Thomas James Lynch Chief Scientific Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
BRISTOL-MYERS SQUIBB COMPANY-4.35%80 190
JOHNSON & JOHNSON0.24%343 400
PFIZER-2.11%244 238
NOVARTIS3.97%225 626
ROCHE HOLDING LTD.5.61%223 510
MERCK AND COMPANY-2.36%194 014